WHO 2017 Priority Pathogens List

Dear All:

The new WHO priority pathogen list for R&D has been released! It’s entirely focused on bacteria both otherwise has a lot of similarity the CDC list. FYI, CARB-X will use both lists going forward. Links to WHO materials are below. I have also prepared a short slide deck (updated on 22 Dec 2017) that shows the WHO, CDC, and ESKAPE pathogens side-by-side.

  • 22 Dec 2017 addendum: see also this blog post regarding the methodology paper published Dec 2017.
  • 11 Feb 2020 addendum: I have updated that deck to also show the CDC 2019 threat list. Get the new deck here, go here for a newsletter about CDC’s update, and go here for a discussion of the problem of setting antibiotic R&D priorities.

Best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust | Follow me on Twitter: @JohnRex_NewAbx

Press release: http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/

Pathogen list: http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf

Share

Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on whatsapp
Share on reddit

Pull incentives in the EU / Statements by Commissioner Kyriakides

Dear All, Stella Kyriakides, the European Commissioner for Health and Food Safety, made some really interesting statements before the European Parliament’s health committee (ENVI) on Thursday of last week (22 April). Per this Exchange of Views on the EP’s multimedia center and this news report, here are some highlights: In the Exchange of Views at 00:03:44, she said: “Later

WHO seeks experts for critical antibiotics advisory group

Dear All, WHO have opened a call for experts to be part of an Advisory Group on their Critically Important Antimicrobial (CIA) List. Background: As discussed in this 12 Oct 2020 newsletter, WHO and FDA’s Center for Veterinary Medicine (CVM) rank antibiotics to determine which can be used in animals vs. those that must preserved for

WHO 2020 clinical/preclinical pipeline review; Chat with WHO’s Peter Beyer

Dear All, WHO have today updated their 2019 clinical/preclinical pipeline review by releasing their 2020 analyses of both the clinical and pre-clinical antibacterial product pipelines (the new 2020 report, the press release). Their 2020 review of antibacterial products in Phase 1 and beyond covers both traditional (n = 43) and non-traditional products (n = 27)

Scroll to Top